Modulation of 11β-Hydroxysteroid Dehydrogenase as a Strategy to Reduce Vascular Inflammation
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Atherosclerosis is a chronic inflammatory disease in which initial vascular damage leads to extensive macrophage and lymphocyte infiltration. Although acutely glucocorticoids suppress inflammation, chronic glucocorticoid excess worsens atherosclerosis, possibly by exacerbating systemic cardiovascular risk factors. However, glucocorticoid action within the lesion may reduce neointimal proliferation and inflammation. Glucocorticoid levels within cells do not necessarily reflect circulating levels due to pre-receptor metabolism by 11β-hydroxysteroid dehydrogenases (11β-HSDs). 11β-HSD2 converts active glucocorticoids into inert 11-keto forms. 11β-HSD1 catalyses the reverse reaction, regenerating active glucocorticoids. 11β-HSD2-deficiency/inhibition causes hypertension, whereas deficiency/inhibition of 11β-HSD1 generates a cardioprotective lipid profile and improves glycemic control. Importantly, 11β-HSD1-deficiency/inhibition is atheroprotective, whereas 11β-HSD2-deficiency accelerates atherosclerosis. These effects are largely independent of systemic risk factors, reflecting modulation of glucocorticoid action and inflammation within the vasculature. Here, we consider whether evidence linking the 11β-HSDs to vascular inflammation suggests these isozymes are potential therapeutic targets in vascular injury and atherosclerosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A transgenic model of visceral obesity and the metabolic syndrome
Masuzaki, H., Paterson, J., Shinyama, H., Morton, N. M., Mullins, J. J., Seckl, J. R., & Flier, J. S. (2001) · Science · doi:10.1126/science.1066285 · Cited by 1,766 · cited 1×
“systemic, glucocorticoid excess and causes visceral obesity, hypertension, diabetes and dyslipidaemia [72, 73], whereas over-expression in liver causes hypertension and mild insulin resistance [74].”
BackgroundSelf-citationDiabetes mellitus and risk of Alzheimer disease and decline in cognitive function
Arvanitakis, Z., Wilson, R. S., Bienias, J. L., Evans, D. A., & Bennett, D. A. (2004) · Archives of Neurology · doi:10.1001/archneur.61.5.661 · Cited by 1,258 · cited 1×
“In a similar manner, age-related cognitive decline (itself associated with impaired glycaemic control [75]) is associated with higher 11β-HSD1 activity in humans [76] and in rodents [77], and 11β-HSD1-deficient mice are protected from age-related cognitive decline (reviewed in [78]).”
BackgroundMorbidity and mortality in Cushing's disease: an epidemiological approach.
Etxabe, J., & Vazquez, J. A. (1994) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1994.tb02486.x · Cited by 622
Masuzaki, H., Yamamoto, H., Kenyon, C. J., Elmquist, J. K., Morton, N. M., Paterson, J. M., Shinyama, H., Sharp, M. G. F., Fleming, S., Mullins, J. J., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17845 · Cited by 434 · cited 1×
“systemic, glucocorticoid excess and causes visceral obesity, hypertension, diabetes and dyslipidaemia [72, 73], whereas over-expression in liver causes hypertension and mild insulin resistance [74].”
BackgroundSelf-citationFaggiano, A., Pivonello, R., Spiezia, S., De Martino, M. C., Filippella, M., Di Somma, C., Lombardi, G., & Colao, A. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021558 · Cited by 358 · cited 2×
“ficial effects of reducing glucocorticoid action separate from effects on the classical systemic risk factors [9].”
Background11β-Hydroxysteroid dehydrogenases and the brain: From zero to hero, a decade of progress
Wyrwoll, C. S., Holmes, M. C., & Seckl, J. R. (2011) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2010.12.001 · Cited by 244
Self-citation11β-hydroxysteroid dehydrogenases: changing glucocorticoid action
Seckl, J. R. (2004) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2004.09.001 · Cited by 185
Self-citationLocalization of 11 beta-hydroxysteroid dehydrogenase type II in human epithelial tissues.
Smith, R. E., Maguire, J. A., Stein-Oakley, A. N., Sasano, H., Takahashi, K., Fukushima, K., & Krozowski, Z. S. (1996) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.81.9.8784076 · Cited by 146
Cai, T.-Q., Wong, B., Mundt, S. S., Thieringer, R., Wright, S. D., & Hermanowski-Vosatka, A. (2001) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/s0960-0760(01)00041-3 · Cited by 98
Cited by
Metformin and inflammation: its potential Beyond glucose-lowering effect
Saisho, Y. (2015) · Endocrine, Metabolic & Immune Disorders-Drug Targets · doi:10.2174/1871530315666150316124019 · Cited by 450
The multifaceted mineralocorticoid receptor
Gomez‐Sanchez, E., & Gomez‐Sanchez, C. E. (2014) · Comprehensive Physiology · doi:10.1002/j.2040-4603.2014.tb00569.x · Cited by 55
Metadata
- Authors
- Hadoke, P. W. F., Kipari, T., Seckl, J. R., & Chapman, K. E.
- Venue
- Current Atherosclerosis Reports
- Published
- 2013-03-20
- Volume
- 15
- Issue
- 5
- Pages
- 320-320
- ISSN
- 1523-3804 (ISSN-L)
- 1534-6242
- OpenAlex
- W2147912438
- Cited by
- 40
- References
- 9
- FWCI
- 5.66
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Modulation of 11β-Hydroxysteroid Dehydrogenase as a Strategy to Reduce Vascular Inflammation. https://app.cochat.ai/papers/10.1007/s11883-013-0320-1
- The paper
- Hadoke, P. W. F., Kipari, T., Seckl, J. R., & Chapman, K. E. (2013). Modulation of 11β-Hydroxysteroid Dehydrogenase as a Strategy to Reduce Vascular Inflammation. Current Atherosclerosis Reports. https://doi.org/10.1007/s11883-013-0320-1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.